title: Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists.
authors.forename: P
authors.initials: P
authors.lastname: Tjernberg
authors.forename: J F
authors.initials: JF
authors.lastname: Van Der Heijden
authors.forename: J C J
authors.initials: JC
authors.lastname: Eikenboom
authors.forename: P H
authors.initials: PH
authors.lastname: Reitsma
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology*; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D005091:Exons; D006470:Hemorrhage / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D011110:Polymorphism, Genetic; D012306:Risk; D012307:Risk Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D014841:von Willebrand Factor / Q000235:genetics*
chemical_list: D000925:Anticoagulants; D014841:von Willebrand Factor; D014812:Vitamin K